Decitabine alters the expression of Mecp2 isoforms via dynamic DNA methylation at the Mecp2 regulatory elements in neural stem cells by Vichithra R B Liyanage et al.
Liyanage et al. Molecular Autism 2013, 4:46
http://www.molecularautism.com/content/4/1/46RESEARCH Open AccessDecitabine alters the expression of Mecp2
isoforms via dynamic DNA methylation at the
Mecp2 regulatory elements in neural stem cells
Vichithra R B Liyanage, Robby M Zachariah and Mojgan Rastegar*Abstract
Background: Aberrant MeCP2 expression in brain is associated with neurodevelopmental disorders including
autism. In the brain of stressed mouse and autistic human patients, reduced MeCP2 expression is correlated with
Mecp2/MECP2 promoter hypermethylation. Altered expression of MeCP2 isoforms (MeCP2E1 and MeCP2E2) is
associated with neurological disorders, highlighting the importance of proper regulation of both isoforms. While
known regulatory elements (REs) within the MECP2/Mecp2 promoter and intron 1 are involved in MECP2/Mecp2
regulation, Mecp2 isoform-specific regulatory mechanisms are unknown. We hypothesized that DNA methylation at
these REs may impact the expression of Mecp2 isoforms.
Methods: We used a previously characterized in vitro differentiating neural stem cell (NSC) system to investigate
the interplay between Mecp2 isoform-specific expression and DNA methylation at the Mecp2 REs. We studied altered
expression of Mecp2 isoforms, affected by global DNA demethylation and remethylation, induced by exposure and
withdrawal of decitabine (5-Aza-2′-deoxycytidine). Further, we performed correlation analysis between DNA methylation
at the Mecp2 REs and the expression of Mecp2 isoforms after decitabine exposure and withdrawal.
Results: At different stages of NSC differentiation, Mecp2 isoforms showed reciprocal expression patterns associated
with minor, but significant changes in DNA methylation at the Mecp2 REs. Decitabine treatment induced Mecp2e1/
MeCP2E1 (but not Mecp2e2) expression at day (D) 2, associated with DNA demethylation at the Mecp2 REs. In contrast,
decitabine withdrawal downregulated both Mecp2 isoforms to different extents at D8, without affecting DNA
methylation at the Mecp2 REs. NSC cell fate commitment was minimally affected by decitabine under tested
conditions. Expression of both isoforms negatively correlated with methylation at specific regions of the Mecp2
promoter, both at D2 and D8. The correlation between intron 1 methylation and Mecp2e1 (but not Mecp2e2) varied
depending on the stage of NSC differentiation (D2: negative; D8: positive).
Conclusions: Our results show the correlation between the expression of Mecp2 isoforms and DNA methylation in
differentiating NSC, providing insights on the potential role of DNA methylation at the Mecp2 REs in Mecp2
isoform-specific expression. The ability of decitabine to induce Mecp2e1/MeCP2E1, but not Mecp2e2 suggests differential
sensitivity of Mecp2 isoforms to decitabine and is important for future drug therapies for autism.
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Methyl CpG Binding Protein 2 (MeCP2) is a key tran-
scriptional regulator in the brain [1]. MECP2 mutations
and expression deficits result in a broad range of neuro-
developmental disorders, including Rett syndrome (RTT)
and autism spectrum disorders [2,3]. In mice (Mecp2) and
humans (MECP2), alternative splicing of a single gene
leads to the generation of two protein isoforms MeCP2E1
and MeCP2E2 (mature transcripts for Mecp2e1 and
Mecp2e2 are shown in Figure 1A) [4,5]. We and others
have shown differential expression of the two Mecp2/
MeCP2 isoforms in mouse brain [5-7]. Recent studies sug-
gest that MeCP2E1 is the most relevant isoform for RTT
pathology [8,9]. Moreover, overexpression of Mecp2e2,
but not Mecp2e1, promotes neuronal cell death [10], im-
plicating the importance of proper regulation of both
Mecp2 isoforms in the brain.
In RTT mouse models, transgenic expression of either
Mecp2 isoform can rescue RTT phenotypes to different
extents [14,15]. However, gene therapy delivery of
MECP2 into the affected cells or drug therapies to in-
duce MECP2 expression has to be carried out with cau-
tion, as even mild overexpression of MeCP2 can lead to
progressive neurological disorders [16,17]. Currently,Figure 1 Schematics of the Methyl CpG binding protein 2 gene (Mecp
(A) Generation of MeCP2 isoforms by alternative splicing; mature Mecp2e1
comprise of exons 2, 3, and 4 (adapted from [4,11]). Exons are denoted as
Mecp2 gene is reported to be regulated by negative and positive REs within
extracted from [12,13]). For our studies we selected a 500-bp region in the pr
upstream of the exon 2. Each sequence was divided into three regions, R1 to
are no CpG dinucleotides in the mouse genomic sequence between R5 andlimited knowledge exists on MECP2/Mecp2 regulation,
with no specific knowledge on possible differential
MECP2/Mecp2 isoform-specific regulatory mechanisms.
MECP2/Mecp2 gene expression is known to be regu-
lated by regulatory elements (REs) within the promoter
and a silencer element within the Mecp2 intron 1
[12,13,18] (Figure 1B). Implying the role of DNA methy-
lation in MECP2 regulation, reduced MECP2 expression
in the brains of male autistic patients correlates with hu-
man MECP2 promoter hypermethylation [2,19]. More-
over, reduced Mecp2 expression in the postnatal murine
brain in response to early maternal separation and stress
is associated with hypermethylation of the mouse Mecp2
promoter [20]. However, possible differential impact of
DNA methylation on MECP2/Mecp2 isoforms is cur-
rently unknown. DNA methylation is a major epigenetic
modification that controls gene expression without af-
fecting the underlying DNA sequences (reviewed in
[21,22]). DNA methylation at the cytosine residues (5-
methylcytosine (5mC)) of the CpG dinucleotides is car-
ried out by DNA methyltransferases (DNMT) and is
generally considered to be a repressive epigenetic modifica-
tion [1,23]. Conversely, 5-hydroxymethylcytosine (5hmC),
which is generated by oxidation of 5mC by TET proteins2), Mecp2e1/e2 transcripts, and known regulatory elements (REs).
transcripts comprise of exons 1, 3, and 4. Mature Mecp2e2 transcripts
Ex. (B) Regulatory elements of the MECP2/Mecp2 gene. The MECP2/
the promoter and a silencer element within the intron 1 (information
omoter upstream of the exon 1 and a 1-kb region in the intron 1
R3 in the Mecp2 promoter and R4 to R6 in the intron 1. Note that there
R6.
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[24,25]. Promoter methylation is mostly associated with
gene silencing [26], while DNA methylation at both in-
tronic and exonic regions are shown to correlate with
isoform-specific transcription by alternative splicing or by
utilizing alternate promoters [27,28].
Treatment with DNA demethylating agents or DNMT/
Dnmt inhibitors such as decitabine (also called 5-Aza-2′-
deoxycytidine) is a commonly used method to study the
role of DNA methylation in gene expression [29,30].
While exposure to decitabine results in DNA demethyla-
tion, its subsequent withdrawal causes remethylation or
methylation reprogramming [29], providing an excellent
platform to uncover the role of DNA methylation in gene
expression.
In vitro differentiation of neural precursor cells/neural
stem cells (NSC) into different brain cell types is utilized
as an acceptable model system to mimic the in vivo
neural development [31-36]. Previously, we used a simi-
lar in vitro NSC differentiation system to report the first
preclinical MECP2 isoform-specific gene therapy vectors,
for future gene therapy applications in Rett syndrome
[35]. Further, we introduced differentiating NSC as a suit-
able in vitro model to study the expression and function of
developmentally important genes such as Meis1 in neural
development [37]. In the current study, we used this previ-
ously characterized system to study the expression and
regulation of Mecp2 isoforms during NSC differentiation.
Investigation of MECP2/MeCP2 expression and func-
tion in neurodevelopmental disorders has been the focus
of intensive research. However, despite the critical im-
portance of precisely controlled levels of MeCP2 expres-
sion in the brain, the underlying regulatory mechanisms
have been understudied. Here, we report the correlation
between the expression of Mecp2 isoforms and DNA
methylation patterns at the Mecp2 REs at different
stages of NSC differentiation. Further, we demonstrate
the effect of dynamic changes in DNA methylation in-
duced by exposure and withdrawal of decitabine on the
expression of Mecp2/MeCP2 isoforms.
Methods
Ethics statement
All experiments were performed in accordance with the
standards of the Canadian Council on Animal Care with
the approval of the Office of Research Ethics of University
of Manitoba. All experimental procedures were reviewed
and approved (protocol number 12–031) by the University
of Manitoba Bannatyne Campus Protocol Management
and Review Committee.
Neural stem cell isolation, culture and differentiation
Embryonic mouse forebrain-derived NSC were isolated
from the forebrains of CD-1 mice at embryonic day (E)14.5 and were cultured according to previously described
methods [35,37]. Briefly, dissected forebrain tissues were
mechanically homogenized in NSC media DMEM/F12
1:1 (Wisent, Quebec, Canada) containing HEPES, glu-
tamine, antibiotic/antimycotic, glucose, recombinant hu-
man epidermal growth factor (rhEGF) (Sigma Aldrich,
Oakville, Ontario, Canada, 20 ng/ml), basic fibroblast
growth factor (bFGF) (Upstate (Millipore), Billerica,
MA, USA, 20 ng/ml), heparin (Sigma Aldrich, Oakville,
Ontario, Canada, 2 μg/ml) and hormone mix. Dissoci-
ated single cells were plated at a density of 105 cells/cm2
in NSC media. The media were refreshed every 48 h and
cells were cultured under these conditions for 7 days to
generate neurospheres. Primary neurospheres were gen-
tly dissociated to single cells by accutase treatment. Dis-
sociated cells were plated on plates coated with growth
factor-reduced matrigel (BD Biosciences, Mississauga,
Ontario, Canada) at a density of 105 cells/cm2 in DMEM
(GIBCO, Life Technologies Inc, Burlington, Ontario,
Canada) and 10% Fetal Bovine Serum (Invitrogen, Life
Technologies Inc, Burlington, Ontario, Canada) in the
absence of rhEGF and bFGF. Cells were differentiated
for 8 days, reported to be sufficient for differentiation of
neuronal and glial cells [35,37], and media were changed
every other day.
Decitabine treatment
At the onset of differentiation on day zero (D0), dissoci-
ated NSC were treated with 2.5 μM decitabine for 48 h.
After two days (D2), the media were replaced with fresh
media that was refreshed every other day for an extra
6 days (until D8). Control cells were cultured under simi-
lar experimental conditions, in the absence of decitabine.
Quantitative measurement of male/female contribution
Genomic DNA from neural stem cells at D0, D2, D8 and
decitabine-treated cells were extracted using the DNeasy
Blood and Tissue kit (Qiagen, Ontario, Toronto, Canada),
as per manufacturer’s instructions. The contribution of
male and female sexes were determined by semiquantita-
tive PCR-based amplification of Sry (sex-determining
region protein gene in the Y chromosome) and Il3 (auto-
somal gene as an internal control) genes, as described pre-
viously [38], using the primers listed in Table 1. The PCR
program consisted of an initial denaturation at 95°C for
4.5 minutes, followed by 33 cycles of 95°C for 35 s, 50°C
for 1 minute, 72°C for 1 minute, and a final extension step
at 72°C for 5 minutes. The amplified products were run
on 1.5% agarose gel and the bands were visualized by eth-
idium bromide staining. The Sry and Il3 PCR products
were identified based on the corresponding sizes (Sry:
402 bp, and Il3: 544 bp). Intensity of the corresponding
bands was quantified using Adobe Photoshop CS5 software.
The contribution of either sex was further determined by
Table 1 List of primers used for PCR
Gene Direction Sequence Reference
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(X-inactive specific transcript) gene, as previously described,
with minor modifications [39]. The PCR program for Xist
included an initial denaturation at 95°C for 5 minutes;
followed by 35 cycles of 95°C for 30 s, 53°C for 30 s, 72°C
for 30 s, and 78°C for 30 s.
Quantitative reverse transcription polymerase chain reaction
RNeasy Mini Kit (Qiagen, Ontario, Toronto, Canada)





























Reverseprotocol. Preparation of cDNA and qRT-PCR were car-
ried out as described previously [40-42]. Transcript levels
of Mecp2 (total), Mecp2e1 [NCBI: NM_001081979.1],
Mecp2e2 [NCBI: NM_010788.3], Dnmt genes (Dnmt1,
Dnmt3a and Dnmt3b), neuronal genes (Tubulin III (Tub
III), NeuN), astrocytic genes (Gfap, S100b), and oligo-
dendrocyte-specific genes (Cnpase, Mbp) were examined
by using gene-specific primers (Table 2), as described pre-
viously [37,43]. The relative expression and fold changes
were calculated as described previously [37]. Two-way
analysis of variance (ANOVA) and the Student t-test were
used to calculate significant differences between untreated
control and decitabine-treated samples.
Immunofluorescence experiments
Immunofluorescence (IF) experiments were performed
according to previously described protocols [7,35,37].
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signals were detected by an Axio Observer Z1 inverted
microscope and LSM710 Confocal microscope from Carl
Zeiss. Images were obtained with AxioVision 4.8 (Carl
Zeiss Canada Ltd. Ontario, Toronto, Canada) and Zen
2009 software and assembled using Adobe Photoshop
CS5 and Adobe Illustrator CS5. For quantification ana-
lysis in neurospheres, three neurospheres were randomly
selected and all of the cells within each neurosphere
were counted based on 4',6-diamidino-2-phenylindole
(DAPI) staining. For cell quantification of differentiating
cells at D2 and D8, 8 to 10 random fields were selected
under the microscope. Approximately 250 cells from the
D2 population and 750 cells from the D8 population
were counted based on DAPI labeling. The cell counting
was done using the ImageJ program.
Nuclear extractions and western blotting
Nuclear extraction from D2 and D8 NSC were carried out
using the NE-PER Nuclear and Cytoplasmic Extraction
Kit (Thermo Scientific, Ontario, Toronto, Canada), as per
the manufacturer’s instructions. Western blot (WB)
experiments were conducted according to previously
described protocols [49-51], and quantification of the
signals was performed as reported [7]. ACTIN or
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was used as a loading control. Student t-test was used to
determine statistical significance between control and
treated cells. Primary and secondary antibodies used for
WB are listed in the Tables 3 and 4, respectively.Table 3 Primary antibodies used
Primary antibody Application and dilution Description
MeCP2 (C-terminal) IF 1:200 Rabbit polyclonal
MeCP2 (C-terminal) WB 1:100 Mouse monoclonal
IF 1:200
MeCP2E1 WB 1:100 Chicken polyclonal
GFAP IF 1:200 Mouse monoclonal
TUBULIN III (TUB III) IF 1:200 Mouse monoclonal
OLIG2 IF 1:200 Rabbit polyclonal
NESTIN IF 1:230 Rat monoclonal
S100B IF 1:100 Mouse monoclonal
CNPase IF 1:100 Mouse monoclonal
MBP IF 1:100 Rabbit polyclonal
NEUN IF 1:200 Mouse monoclonal
KI67 IF 1:200 Rabbit polyclonal
5mC Dot blot 1:1,000 Mouse monoclonal
IF 1:200
5hmC Dot blot 1:1,000 Rabbit polyclonal
MeCP2, Methyl CpG binding protein; GFAP, Glial fibrillary acidic protein; OLIG2, Olig
3'-phosphodiesterase, MBP, Myelin basic protein; NEUN, NEUronal Nuclei; 5mC, 5-m
Western blot.DNA dot blot assay for 5mC and 5hmC
Genomic DNA was isolated using the DNeasy Blood and
Tissue kit (Qiagen, Ontario, Toronto, Canada). DNA dot
blot was performed using a previously described protocol
[52], with minor modifications. The DNA blotted mem-
branes were probed with either 5mC or 5hmC antibody
(Tables 3 and 4). Total DNA levels were detected by stain-
ing the same membrane with 0.02% methylene blue (MB)
in 0.3 μM sodium acetate (pH 5.2). Adobe Photoshop CS5
software was used to quantify dot blot signals.
Bisulfite pyrosequencing
Genomic DNA was isolated as described in the previous
section. Primer design and bisulfite pyrosequencing ex-
periments were conducted as a service by The Hospital
for Sick Children (SickKids), Toronto, Canada, as re-
ported elsewhere [53], using the primers listed in Table 5.
The regions analyzed for the methylation patterns are
shown in Figure 1B. Specific CpG dinucleotides that are
analyzed within each region are shown in Additional file 1.
Correlation analysis
The correlation between DNA methylation at the Mecp2
REs and expression of Mecp2 isoforms was determined
using the Pearson’s correlation analysis and linear regres-
sion. The Pearson’s correlation coefficient (r) was calcu-
lated for average methylation against each Mecp2 isoform,
over entire regions and for individual CpG sites within
each region. The strength of correlation was considered as
follows: weak, 0 < r <0.3; moderate, 0.3 < r <0.4; strong,Source
Millipore, Billerica, MA, USA, 07-013
Abcam, Ontario, Toronto, Canada, Ab50005
Custom-made [7]
Invitrogen, Life Technologies Inc, Burlington, Ontario, Canada 421262
Chemicon, Millipore, Billerica, MA, USA MAB1637
Millipore, Millipore, Billerica, MA, USA, AB9610
Developmental Studies Hybridoma Bank, Rat-401c
Abcam, Ontario, Toronto, Canada, ab4066
Covance, SMI-91R
Abcam, Ontario, Toronto, Canada, ab40390
Millipore, Billerica, MA, USA, Mab377
Santa cruz, Dallas, Texas, USA, sc-15402
Abcam, Ontario, Toronto, Canada, Ab73938
Active Motif, 39769
odendrocyte lineage transcription factor 2; CNPase, 2',3'-Cyclic-nucleotide
ethylcytosine; 5hmc, 5-hydroxymethylcytosine; IF, Immunofluorescence; WB,
Table 4 Secondary antibodies used
Secondary antibody Application and dilution Source
FITC conjugated goat anti rabbit IgG IF 1:400 Jackson Immunoresearch, PA, USA, 111-095-144
Rhodamine Red-X conjugated goat anti mouse IgG IF 1:400 Jackson Immunoresearch, PA, USA, 115-259-146
Dylight 649 conjugated goat anti chicken IgY IF 1:400 Jackson Immunoresearch, PA, USA, 103-485-155
Dylight 649 conjugated donkey anti goat IgG IF 1:400 Jackson Immunoresearch, PA, USA, 705-494-147
Alexa Fluor 594 conjugated donkey anti mouse IgG IF 1:1,000 Life Technologies Inc, Ontario, Canada, 987237
Alexa Fluor 448 conjugated donkey anti rabbit IgG IF 1:1,000 Life Technologies Inc, Ontario, Canada, 913921
Peroxidase-Affinipure Gt anti-mouse IgG WB 1:7,500 Jackson ImmunoResearch, PA, USA, 115-035-174
Dot blot 1:7,500
IF, Immunofluorescence; WB, Western blot.
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indicates an inverse/negative correlation whereas a posi-
tive r-value indicates direct/positive correlation. Statistical
significance was determined at P <0.05.
Results
Dynamic expression of Mecp2 isoforms during NSC
differentiation and DNA methylation patterns at the
Mecp2 regulatory elements
Primary neural stem cells were isolated from the embry-
onic forebrain at E14.5 and were cultured in the presence
of growth factors to generate primary neurospheres. After
7 days in culture, primary neurospheres were dissociated
and cultured under differentiation conditions for 8 days,
reported to be sufficient for differentiation of both neur-
onal and glial cells [35,37] (Figure 2A). In agreement withTable 5 Primers used in bisulfite pyrosequencing
Mecp2 region Sequen
Region 1 F: 5′-TGG
R: 5′-CG
S: 5′-AG
Region 2 F: 5′-AG
R: 5′-CG
S: 5′-AA
Region 3 F: 5′-GG
R: 5′-CG
S: 5′-AG
Region 4 F: 5’-GTT
R: 5′-CG
S: 5′-AG
Region 5 F: 5′-AG
R: 5′-CG
S: 5′-AG
Region 6 F: 5′-GA
R: 5′-CG
S: 5′-GTT
F: Forward PCR primer, R: Reverse PCR primer (Biotinylated), S: Sequencing primer.our previous report [37] the proliferating primary neuro-
spheres expressed NESTIN and KI67 (Figure 2B). Similar
to our previous reports [35,37] differentiated NSC at D8
consisted of a mixed population of neurons, astrocytes,
and oligodendrocytes (Figure 2C). The composition of the
D8 population was determined by detection of cell type-
specific markers (TUB III (4.7% ± 0.8 mean ± standard
error of the mean (SEM)), Glial fibrillary acidic protein
(GFAP) (54.4% ± 1.1), S100B (15.9% ± 2.7), 2',3'-Cyclic-nu-
cleotide 3'-phosphodiesterase (CNPase) (1.6% ± 0.2), Myelin
basic protein (MBP) (2.6% ± 0.42), Oligodendrocyte lineage
transcription factor 2 (OLIG2) (36.2% ± 1.8) and KI67
(92.4% ± 1.3)) by immunofluorescence (Figure 2C). KI67 is
not a cell type-specific marker, but rather reflects the frac-
tion of cycling cells within differentiating NSC. Indi-



















Figure 2 Characterizing in vitro neural stem cells to study Methyl CpG binding protein 2 (MeCP2) expression. (A) Schematic representation of
in vitro neural stem cell (NSC) differentiation. (B) Detection of (a) NESTIN+ and (b) KI67+ cells in self-renewing neurospheres. Scale bars represent
20 μm. (C) Immunofluorescent detection of different cell-type markers in the day 8 (D8) population (a) TUBULIN III (TUB III): neurons, (b) Glial fibrillary
acidic protein (GFAP): astrocytes, (c) S100B: mature astrocytes, (d) 2',3'-Cyclic-nucleotide 3'-phosphodiesterase (CNPase): oligodendrocytes, (e) Myelin
basic protein (MBP): oligodendrocytes, (f) Oligodendrocyte lineage transcription factor 2 (OLIG2): early oligodendrocytes and progenitors, and (g) KI67:
proliferating cells. Scale bars represent 10 μm. The percentages represent average number of cells from three individual experiments (n = 3 ± standard
error of the mean). (D) (a) Immunofluorescent detection of MeCP2 in a sectioned primary neurosphere. Scale bar represents 20 μm. (b) Double labeling
of MeCP2 and NESTIN within primary neurosphere cells. Scale bar represents 5 μm. (E) Immunofluorescent detection of MeCP2 in D8 cell types: (a)
TUB III, (b) GFAP, (c) S100B, (d) CNPase, (e) MBP, (f) OLIG2, and (g) KI67. Scale bars represent 2 μm.
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also detected in D2 cells (Additional file 2). Our detection
of KI67 in the majority of cells at D8 indicates that al-
though most differentiating NSC are actively dividing,
fewer than 10% of cells are post-mitotic and may include
neurons (TUB III+) or non-proliferating cells committed
towards neuronal cell fate. Taken together, this in vitro
NSC differentiation system provided a suitable model sys-
tem consisting of the three main neural cell types (neurons,
astrocytes and oligodendrocytes) in the brain to study
Mecp2/MeCP2 isoforms during neural differentiation.First, we confirmed MeCP2 expression in neurospheres
at D0 and differentiated NSC at D8 by IF studies. We used
an antibody that was raised against the MeCP2 C-
terminus and recognizes both isoforms. Characteristic
punctate nuclear expression of MeCP2 was detected in
41% of neurosphere cells (Figure 2D, a), which were posi-
tive for the NSC marker NESTIN (Figure 2D, b). At D8 of
NSC differentiation, MeCP2 protein was detected in all
cell types in the D8 differentiated progenies, including
neurons, astrocytes, and oligodendrocytes (Figure 2E).
Indicating the expression of MeCP2 in proliferating cells,
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(Figure 2E, g). The detected nuclear MeCP2 signals were
enriched at the heterochromatin-rich regions of all three
cell types. These observations are consistent with our pre-
vious reports on MeCP2 nuclear expression in in vivo dif-
ferentiated primary neurons and astrocytes [7].
Next, we investigated Mecp2 isoform-specific tran-
script expression at three stages of NSC differentiation:
undifferentiated cells (D0), cells at an early stage of differ-
entiation (D2), and cells at a later stage of differentiation
(D8). Distinct and mirror-like (reciprocal) transcript ex-
pression patterns for Mecp2 isoforms were observed dur-
ing NSC differentiation (D0, D2, and D8) (Figure 3A),
suggesting possible differential regulation of these iso-
forms during NSC differentiation. Expression of Mecp2e1
was reduced from D0 to D2 (2.7-fold, P <0.001) and was
slightly elevated from D2 to D8. In contrast, Mecp2e2 ex-
pression increased from D0 to D2 (3.1-fold, P <0.05), but
declined from D2 to D8 (4.2-fold, P <0.01). At each of
these studied differentiation stages, the expression ratio
between the two isoforms (Mecp2e1/Mecp2e2) varied sig-
nificantly (D0, 5.99; D2, 0.69; D8, 4.62) (Additional file 3).
At D0 and D8, Mecp2e1 expression was significantly
higher than Mecp2e2 (D0, P <0.01, and D8, P <0.05). In
contrast at D2, Mecp2e2 expression was significantly
higher than Mecp2e1 (D2, P <0.05). These observations
imply differential regulation of Mecp2 isoforms and pos-
sible changes in alternative splicing of Mecp2 at different
stages of NSC differentiation.
MECP2/Mecp2 expression is known to be regulated by
REs found within its promoter and intron 1. The altered
MeCP2 expression in autistic patients and in mouseFigure 3 Methyl CpG binding protein 2 gene (Mecp2) isoform-specific
regulatory elements during neural stem cell (NSC) differentiation. (A)
differentiation: n = 3 ± standard error of the mean (SEM). Significant differen
methylation over Mecp2 promoter and intron 1 regions at day 0 (D0), day
promoter regions R1, CpG island contains 13 CpG sites; R2, 4 CpG sites; R3,
R6, 2 CpG sites; n = 3 ± SEM. Significant differences: **P <0.01; *P <0.05. Gapbrains subjected to stress is correlated with increased
MECP2/Mecp2 promoter methylation [2,12,13,18-20].
Therefore, we hypothesized that DNA methylation at the
Mecp2 promoter and intron 1 might impact Mecp2
isoform-specific expression. For DNA methylation ana-
lysis by bisulfite pyrosequencing, we selected three regions
within the Mecp2 promoter (named R1 to R3, hereafter)
and three regions within the intron 1 (named R4 to R6,
hereafter) (Figure 1B). These regions harbored different
numbers of CpG sites; promoter regions R1: CpG island
contains 13 CpG sites; R2: 4 CpG sites; R3: 2 CpG sites,
and intron 1 regions R4: 1 CpG site; R5: 1 CpG site; and
R6: 2 CpG sites.
Pyrosequencing analysis of R1-R6 indicated that down-
regulation of Mecp2e1 and upregulation of Mecp2e2
from D0 to D2 were associated with slight, but significant
demethylation of Mecp2 promoter R1 (2.3%, P <0.05).
Similarly, upregulation of Mecp2e1 and downregulation of
Mecp2e2 from D2 to D8 were associated with hyperme-
thylation ofMecp2 intron 1 R5 (2.4%, P <0.01) (Figure 3B).
Detected expression changes in Mecp2 isoforms from D0
to D8 were associated with demethylation of Mecp2 pro-
moter R1 (2.6%, P <0.05), and hypermethylation of Mecp2
intron 1 R4 (4.6%, P <0.05). In all cases, the differences in
average percentage methylation between D0, D2 and D8
were relatively small, but statistically significant and ran-
ging between 2 to 5%. Previous reports have shown that
an increase in the overall MECP2 promoter methylation
by approximately 2.0 to 2.5% in male autistic patients cor-
relates with significantly reduced MECP2 expression levels
[2]. In mouse brain exposed to maternal separation and
stress, DNA methylation changes that are as little as 2 totranscript expression and DNA methylation at the Mecp2
Analysis of Mecp2e1 and Mecp2e2 transcript levels during NSC
ces: ***P <0.001; **P <0.01; *P <0.05. (B) Average percentage
2 (D2) and day 8 (D8) during NSC differentiation. The regions are
2 CpG sites, and intron 1 regions R4, 1 CpG site; R5, 1 CpG site; and
dh, glyceraldehyde-3-phosphate dehydrogenase gene.
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sociated with significantly reduced MeCP2 expression
[20]. As even slightly altered MECP2/Mecp2 promoter
methylation (2 to 5%) affects MECP/Mecp2 gene expres-
sion in the human and mouse brain, it is likely that the
statistically significant changes detected in the present
study might be biologically important for Mecp2e1 and/or
Mecp2e2 expression.
As mentioned, the ratio of Mecp2 splice variants was
changed at different stages of NSC differentiation. There-
fore, we performed Pearson's correlation analysis between
Mecp2e1/Mecp2e2 expression ratio and DNA methylation
at R1, R4 and R5 (the three regions that showed sig-
nificant changes) during NSC differentiation. Pearson’s
correlation coefficient (r) represents the strength of correl-
ation, with negative r indicating inverse correlation, and
positive r indicating direct correlation between DNA
methylation and the Mecp2e1/Mecp2e2 splice ratio. We
detected a statistically significant positive correlation
(r >0.9, P <0.01) betweenMecp2e1/Mecp2e2 splice ratio at
D2 and DNA methylation at intron 1 R4 (Additional file 3).
Although it is possible that intron 1 (R4) may play a role
in alternative splicing of Mecp2, further investigations are
required to establish the involvement of DNA methylation
inMecp2 transcriptional splicing.
As MECP2/Mecp2 is an X-linked gene, it is possible
that the observed changes in Mecp2 expression are due
to a shift in the number of cells derived from male and
female embryos. To exclude such a possibility, we deter-
mined the contribution from the male/female embryonic
cells during NSC differentiation using a semiquantitative
PCR-based method. Genomic DNA was extracted from
each differentiation stage and subjected to PCR analysis
for the presence of the Sry gene found in the Y chromo-
some. The autosomal gene Il3 was used an internal con-
trol. The adult male brain cortex was used as a positive
control for the presence of the male genomic DNA
(Additional file 4: Figure S4A). We did not observe sta-
tistically significant changes in the ratio of Sry/Il3 in the
cells collected at different stages of differentiation, indi-
cating that the ratio of male/female differentiating NSC
were unchanged (Additional file 4: Figure S4B). To fur-
ther confirm the contribution from the male/female gen-
der, we tested the transcript levels of Xist gene (the gene
is involved in X-chromosome inactivation) by qRT-PCR.
We did not detect any significant change in Xist gene
expression at different stages of NSC differentiation
(Additional file 4: Figure S4C). These results indicate
that our observed changes in Mecp2 expression are not
due to altered contribution of male and female cells.
Taken together, our results suggest a possible link be-
tween the Mecp2 isoform-specific expression and DNA
methylation at the Mecp2 REs within the Mecp2 pro-
moter and intron 1 during NSC differentiation.Decitabine exposure leads to Mecp2e1 upregulation but
its withdrawal downregulates both Mecp2 isoforms to
different extents
To further study the impact of DNA demethylation/
remethylation in Mecp2 isoform-specific expression, we
treated dissociated neurosphere cells with 2.5 μM decita-
bine for 48 h, at the onset of NSC differentiation (D0)
(Figure 4A). At D2, decitabine was withdrawn from the
media and cells were kept in culture for another 6 days
until D8, to study the effect of DNA remethylation
(Figure 4A). First, as a proof of principle, we verified
whether decitabine acted as a DNA demethylating agent
in our system. Global change in DNA methylation was
determined by IF for 5mC and DNA dot blot assay for
both 5mC and 5hmC. As expected, IF experiments
showed that 5mC nuclear signals were noticeably lower in
decitabine-treated NSC compared to D2 control untreated
cells (Figure 4B). DNA dot blot assays indicated that deci-
tabine treatment resulted in reduced 5mC levels (3.79-
fold, P <0.05), with slight but statistically insignificant
increase in 5hmC levels (Figure 4C-D). In contrast, decita-
bine withdrawal led to re-establishment of global DNA
methylation (5mC) at D8 as detected by IF (Figure 4F).
Furthermore, DNA dot blot assay showed DNA methyla-
tion reprogramming upon decitabine withdrawal, with
elevated 5mC levels (1.5-fold, P <0.05), and relatively un-
changed 5hmC levels in decitabine-treated NSC compared
to controls (Figure 4G-H). Although globally altered 5mC
levels were expected following decitabine treatment in
agreement with previous studies [54,55], the observed ef-
fect of decitabine to slightly increase 5hmC levels was
novel and might be biologically important.
DNA demethylating agents can function as cytosine
analogues and/or as Dnmt/DNMT inhibitors [56]. There-
fore, we investigated Dnmt expression levels in decitabine-
treated differentiating NSC by qRT-PCR. In accordance
with reduced DNA methylation levels at D2, decitabine
treatment caused significant inhibition of transcript levels
of all three DNA methyltransferases (Dnmt1, 1.7-fold,
P <0.05; Dnmt3a, 1.5-fold, P <0.05 and Dnmt3b, 2.5-fold,
P <0.01) (Figure 4E). Even though we anticipated that de-
citabine withdrawal would restore Dnmt levels, only
Dnmt1 levels were elevated (2.2-fold, P <0.05), whereas
both Dnmt3a (1.4-fold, P <0.05) and Dnmt3b (1.8-fold,
P = 0.06) levels remained inhibited (Figure 4I). In sum-
mary, these results indicate that decitabine functions as a
DNA demethylating agent in differentiating NSC and glo-
bally affects DNA methyl marks. Additionally, our data in-
dicate that decitabine withdrawal would lead to DNA
methylation reprogramming in differentiating NSC.
Next, we investigated possible changes in Mecp2/
MeCP2 expression induced by decitabine. Quantitative
RT-PCR experiments indicated that decitabine treatment
at D2 caused slight but statistically significant upregulation
Figure 4 Effect of decitabine on global DNA methylation (5mC and 5hmC) and Dnmt genes in differentiating neural stem cells (NSC).
(A) Schematic representation of decitabine treatment. Briefly, 2.5 μM of decitabine was added to dissociated neurospheres on day 0 (D0) at the
onset of NSC differentiation for 48 h, and the treatment was withdrawn at D2. Cells were kept in culture till D8. Top panel (B-E), after exposure to
decitabine at D2. (B) Immunofluorescent detection of DNA methylation using 5-methylcytosine (5mC) antibody. Decitabine caused reduced levels
of DNA methylation, note the presence of 4',6-diamidino-2-phenylindole (DAPI) signals in decitabine-treated cells with no 5mC signal. Scale bars
represent 5 μm. (C) Detection of overall DNA methylation levels by DNA dot blot with antibodies specific for (a) 5mC, (b) 5-hydroxymethylcytosine
(5hmC). (D) Quantification of the 5mC and 5hmC levels after decitabine exposure. (E) Detection of Dnmt transcript levels by qRT-PCR. Bottom panel
(F-I), after withdrawal of decitabine at D8. (F) DNA methylation detection by immunofluorescence using 5mC antibody. Scale bars represent 5 μm.
(G) Detection of global DNA methylation levels by DNA dot blot, (a) 5mC, (b) 5hmC. (H) Quantification of 5mC and 5hmC levels after withdrawal of
decitabine. (I) Detection of Dnmt transcript levels by qRT-PCR. Fold changes are calculated relative to transcript levels at D2 or D8 control; n = 3 ±
standard error of the mean. Significant differences from control: **P <0.01; *P <0.05. MB, methylene blue (used for visualizing total DNA).
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nificant increased levels of the total Mecp2 (1.2-fold, P =
0.5), and unchanged levels of Mecp2e2 (Figure 5A). Ana-
lysis of protein levels by WB showed that decitabine up-
regulated total MeCP2 (2.5-fold, P <0.05), and MeCP2E1
(3.1-fold, P <0.05) protein expression (Figure 5B-C). How-
ever, the lack of an antibody specific for MeCP2E2 limited
our investigation of MeCP2E2 protein levels. Correlation
analysis of transcript and protein levels of Mecp2/MeCP2
at D2 indicated significant correlation between the de-
tected transcript and protein expression (Mecp2/MeCP2
(r= 0.97, P <0.05) andMecp2e1/MeCP2E1 (r= 0.98, P <0.01);
Figure 5G).In contrast to D2, withdrawal of decitabine at D8 sig-
nificantly downregulated the transcript expression levels
of Mecp2e1 (1.92-fold, P <0.001), Mecp2e2 (1.39-fold,
P <0.05) and the total Mecp2 (1.52-fold, P <0.01)
(Figure 5D). Similar to the transcript levels, decitabine
withdrawal resulted in downregulation of total MeCP2
(3.2-fold, P <0.001), and MeCP2E1 (4.3-fold, P <0.05)
protein expression levels (Figure 5E-F). A similar correl-
ation analysis between transcript and protein levels of
Mecp2/MeCP2 at D8 did not show any statistically sig-
nificant correlation (Mecp2/MeCP2 (r = 0.6, P = 0.2), and
Mecp2e1/MeCP2E1 (r = 0.6, P = 0.3); Figure 5H). These
observations emphasize that even minor change in
Figure 5 (See legend on next page.)
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Figure 5 Effect of decitabine exposure and withdrawal on Methyl CpG binding protein gene (Mecp2/MeCP2) expression. (A-C), After
exposure to decitabine at D2. (A) Analysis of Mecp2 (total), Mecp2e1 and Mecp2e2 transcript levels by qRT-PCR. (B) Detection of MeCP2 (total)
protein expression levels by western blot; n = 2 ± standard error of the mean (SEM). (C) Detection of MeCP2E1 protein expression levels by
western blot; n = 2 ± SEM. (D-F), After withdrawal of decitabine at day 8 (D8). (D) Analysis of total Mecp2, Mecp2e1 and Mecp2e2 transcript levels
by qRT-PCR. (E) Detection of MeCP2 (total) protein expression levels by western blot. (F) Detection of MeCP2E1 protein expression levels by
western blot. (G-H) Pearson's correlation analysis of the relation between Mecp2 transcript levels and MeCP2 protein levels at D2 (G) and D8 (H);
r = Pearson’s correlation coefficient, r2 = coefficient of determination. (I) Transcript detection of cell type-specific markers for neurons (Tub III,
NeuN); astrocytes (Gfap, S100b); oligodendrocytes (Cnpase, Mbp) by qRT-PCR in D2 control and decitabine-treated cells. (J) Quantification of
neurons, astrocytes and oligodendrocytes using cell type-specific markers by immunofluorescence in D2 control and decitabine-treated cells.
(K) Transcript detection of cell type-specific markers for neurons (Tub III, NeuN); astrocytes (Gfap, S100b); oligodendrocytes (Cnpase, Mbp) by qRT-PCR
in D8 control and decitabine-treated cells. (L) Quantification of neurons, astrocytes and oligodendrocytes using cell type-specific markers in
D8 control and decitabine-treated cells. (M) Comparison of immunofluorescent detection of (a) Glial fibrillary acidic protein (GFAP) and (b) S100B
between control and decitabine-treated cells. Images were taken at the same exposure time. Scale bars represent 20 μm. For all the panels, fold
changes are calculated relative to expression levels at D2 or D8 controls. Significant differences from controls: ****P <0.0001; ***P <0.001; **P <0.01;
*P <0.05, n = 3 ± SEM, unless specifically mentioned.
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can result in significantly altered MeCP2 protein expres-
sion levels.
Next, we aimed to study whether the detected changes
in Mecp2/MeCP2 expression were due to changes in cell
population in response to decitabine treatment. There-
fore, we studied the effect of decitabine on cell fate com-
mitment of differentiating NSC at D2 and D8. After
decitabine exposure at D2, we examined the expression
of cell type-specific markers (neurons: Tub III, NeuN; as-
trocytes: Gfap, S100b; oligodendrocytes: Cnpase, Mbp)
at the transcript levels by qRT-PCR. Comparing the con-
trol and decitabine-treated cells, we did not detect any
statistically significant change in these cell type-specific
genes, except for significant downregulation of Cnpase
(9-fold, P <0.01) (Figure 5I). In order to determine
whether any of these detected changes in transcript
levels are represented in the number of cells expressing
each corresponding cell type-specific marker, we per-
formed IF experiments with specific antibodies against
these markers (Figure 5J). IF experiments showed that
there was no significant change in the number of TUB
III+, GFAP+, CNPase+, or MBP+ cells. However, we did
not find any NEUN+, or S100B+ cells in the control or
decitabine-treated populations at D2, probably because
these cells are still in the early stages of differentiation
(Figure 5J). In the D8 population, decitabine treatment
led to insignificant changes in the transcript levels for all
neuronal and oligodendrocyte markers compared to
control untreated cells. Additionally, Gfap expression
in decitabine-treated cells was downregulated 5.5-fold,
whereas S100b expression was upregulated to a similar
extent (6-fold) (Figure 5K). Quantification of differenti-
ated neurons, astrocytes and oligodendrocytes at D8 by
IF did not show any significant change in the cell-fate
commitment of these cells (Figure 5L). However, re-
duced Gfap expression in decitabine-treated cells with-
out any changes in the number of GFAP+ cells might beexplained by the reduced intensity of GFAP staining
relative to the control astrocytes, since the images were
taken at the same exposure level (Figure 5M, a). Simi-
larly, the significant upregulation of S100b transcript
levels by decitabine with no change in the number of
S100B+ cells could be explained by the increased inten-
sity of S100B in decitabine-treated cells, when the im-
ages were taken at the same exposure time (Figure 5M, b).
Taken together, these results suggest that decitabine
has minimal effect on the differentiated number of
neurons, astrocytes and oligodendrocytes under the
described conditions. They further suggest that the
detected changes in Mecp2 expression are not likely
due to altered population of differentiating cell types.
Next, we investigated whether the observed altered
Mecp2/MeCP2 expression was due to changes in the
number of cells deriving from male and female embryos.
Detection of Sry and Il3 by PCR indicated that the ratio
of Sry/Il3 was relatively similar in D2 control and
decitabine-treated populations (Additional file 4: Figure
S4D). Similar PCR analysis at D8 also showed no signifi-
cant differences in the ratio of Sry/Il3 between D8 control
and decitabine-treated cells (Additional file 4: Figure S4E).
Furthermore, qRT-PCR analysis of the Xist gene expres-
sion in both D2 and D8 populations with and without
decitabine treatment showed no significant change in Xist
transcript expression levels between the control and
decitabine-treated cells (Additional file 4: Figure S4F-G).
Therefore, these results indicate that the observed changes
in Mecp2/MeCP2 expression in response to decitabine ex-
posure and withdrawal are not due to a shift in the num-
ber of cells deriving from male/female embryos.
Taken together, our data so far indicate that a single
administration of decitabine for 48 h induces Mecp2e1/
MeCP2E1, MeCP2 (total) expression, whereas its with-
drawal downregulates Mecp2 (total)/MeCP2 (total),
Mecp2e1/MeCP2E1, and Mecp2e2 expression with min-
imal change in NSC differentiation.
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the Mecp2 regulatory elements
As mentioned earlier, DNA methylation changes at the
overall MECP2 promoter and individual CpG sites
within the MECP2/Mecp2 promoter are associated with
altered MECP2/Mecp2 expression [2,19,20]. Therefore,
we investigated whether altered expression of Mecp2Figure 6 Bisulfite pyrosequencing analysis of DNA methylation at the
after decitabine treatment. (A) Effect of decitabine exposure at D2 on th
promoter regions are (a) R1, (b) R2, (c) R3, and the three intron 1 regions a
average methylation over the entire region 2 (R2) (a), and intron 1 (R4 to R
standard error of the mean. (C) Effect of decitabine withdrawal at D8 on p
promoter regions (a) R1, (b) R2 and (c) R3, and intron 1 regions (d) R4, (e) R
methylation over entire region 2 (R2) (a), and intron 1 (R4 to R6) (b).isoforms in our NSC system are associated with change
in DNA methylation at the Mecp2 REs found within the
Mecp2 promoter and intron 1. Bisulfite pyrosequencing
analysis showed that decitabine treatment (D2) caused
no significant change in the percentage DNA methylation
at the Mecp2 promoter R1 and R3 (Figure 6A, a, c). How-
ever, decitabine caused demethylation of all individualMethyl CpG binding protein 2 gene (Mecp2) regulatory elements
e percentage DNA methylation of Mecp2 regulatory regions. The three
re (d) R4, (e) R5, and (f) R6. (B) Effect of decitabine exposure on
6) (b). Significant differences from controls: **P <0.01; *P <0.05; n = 3 ±
ercentage methylation of Mecp2 regulatory regions. The regions are
5 and (f) R6. (D) Effect of decitabine withdrawal on average DNA
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CpG3, 3.1%; CpG4, 4.28%) (Figure 6A, b), as well as the
average R2 percentage DNA methylation (3.83%, P <0.05)
(Figure 6B, a). Similarly, decitabine caused demethylation
of individual CpG sites at the intron 1 R4 (15.8%, P <0.05),
R5 (13.08%, P <0.05), and R6 (CpG1, 8.01%, P <0.01;
CpG2, 3.8%, P = 0.4) (Figure 6A, d-f), with significant
demethylation at the entire intron 1 (10.37%, P <0.05)
(Figure 6B, b). These results indicated that decitabine in-
duced significant DNA demethylation at both the Mecp2
promoter and intron 1, at the individual CpG sites and the
overall DNA methylation. As mentioned earlier, this de-
tected DNA demethylation was associated with significant
upregulation of Mecp2e1 isoform, but not Mecp2e2.
Therefore, it is possible that the observed changes in
DNA methylation at the studied REs contribute to the up-
regulation of Mecp2e1.
Similar bisulfite pyrosequencing analysis at D8 indi-
cated that the three Mecp2 promoter regions (R1 to R3)
and intron 1 regions (R4 to R6) were remethylated and
DNA methylation was almost re-established following
decitabine withdrawal (Figure 6C). Analyzing the average
DNA methylation over the Mecp2 promoter R2 and the
entire intron 1 (which were demethylated at D2), we ob-
served no significant differences in DNA methylation be-
tween D8 control and decitabine-treated cells (Figure 6D).
Despite the fact that DNA remethylation is expected to re-
store the gene expression levels, expression of bothMecp2
isoforms were significantly downregulated. This observa-
tion implies that at D8, other regulatory mechanisms apart
from promoter/intron 1 DNA methylation might be in-
volved in downregulatingMecp2 expression.
Taken together, these results show that the induced
Mecp2e1 (but not Mecp2e2) expression is associated
with reduced DNA methylation at the Mecp2 REs and
decreased global 5mC DNA methylation. Hence, our
findings implicate the possible role of Mecp2 gene-
specific DNA demethylation at the specific REs on the
expression of Mecp2e1/MeCP2E1, and MeCP2 (total) at
D2. Moreover, altered expression of Mecp2 isoforms
without any change in DNA methylation at the Mecp2
REs at D8 imply that mechanisms other than DNA
methylation could be involved in downregulating Mecp2
isoforms.
Mecp2 isoform-specific expression correlates with DNA
methylation at the Mecp2 regulatory elements
In order to establish a link between Mecp2 isoform-
specific expression and DNA methylation, we performed
Pearson's correlation analysis by comparing normalized
(log2) expression of Mecp2 in each dataset to the re-
spective average percentage methylation levels over en-
tire regions, as well as methylation at individual CpG
sites (from both control and decitabine-treated cells).First, we tested whether average DNA methylation of
the entire Mecp2 promoter (R1 to R3), and intron 1 (R4
to R6) regions correlate with Mecp2e1 and Mecp2e2 ex-
pression at D2 in control and decitabine-treated cells.
We observed a significant negative correlation between
Mecp2e1 expression and the average methylation at R1,
R3 and R5 (r > −0.9, P <0.05). Correlation between
Mecp2e1 upregulation and significant demethylation at
R5, induced by decitabine at D2, suggests a possible con-
tribution of R5 in upregulating Mecp2e1. On the other
hand, Mecp2e2 showed significant negative correlation
only with R3 methylation (r > −0.9, P <0.05) (Figure 7A, a),
that remained unchanged at D2, and this could explain
the unaffected Mecp2e2 expression at D2.
Similar correlation analysis at D8 (in control D8 and
decitabine-treated cells), indicated that Mecp2e1 shows
a significant negative correlation with average DNA
methylation at the promoter R1 (r > −0.7, P <0.05), R2
(r > −0.8, P <0.05) and R3 (r > −0.7, P = 0.06, close to sig-
nificant) and a significant positive correlation with the
average DNA methylation at the intron 1 R6 (r >0.9,
P <0.001) (Figure 7A, b). In contrast, Mecp2e2 did not
show any significant correlation with any of the promoter
regions (R1 to R3), but showed a significant positive
correlation with the average methylation at intron 1 R4
(r >0.9, P <0.05) and R6 (r >0.9, P <0.01). This divergence
in the correlation patterns (negative and positive depend-
ing on the stage of differentiation), might imply a potential
dynamic role of DNA methylation in regulating Mecp2
isoforms at different stages of NSC differentiation.
Last, we investigated whether individual CpG sites
within the studied regions (R1 to R6) showed specific
correlation with either Mecp2 isoform (Figure 7B-C).
Implicating the possible role of promoter R1 and R2 in
mainly regulating Mecp2e1 (major isoform) at both D2
and D8, we observed a negative correlation between
CpG methylation and Mecp2e1 expression at several
CpG sites (r > −0.8, P <0.05) (Figure 7B, a, and 7C, a). At
D2, unlike other REs, the average methylation over R3
showed an equally strong negative correlation with both
Mecp2e1 (r = −0.94, P <0.05) and Mecp2e2 (r = −0.98,
P <0.01) (Figure 7A, a). Therefore, we studied the
two individual CpG sites located within R3 far apart
from each other, which were differentially methylated
(CpG1, approximately 10% and CpG2, approximately 30%)
(Figure 6A, c). Interestingly, CpG1 showed a significant
negative correlation with Mecp2e1 (r = −0.9, P <0.05),
while CpG2 showed a significant negative correlation with
Mecp2e2 (r = −0.9, P <0.01) (Figure 7B, c). Further con-
firming the potential role of these two CpG sites within
R3 in Mecp2 isoform-specific expression, a similar correl-
ation (CpG1: Mecp2e1, r = −0.85, P <0.05; CpG2: Mecp2e2,
r = −0.87, P <0.05) was observed at D8 (Figure 7C, c). The
studied intron 1 regions seemed to have preferential
Figure 7 (See legend on next page.)
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Figure 7 Correlation analysis between DNA methylation at the Methyl CpG binding protein 2 gene (Mecp2) regulatory elements and
Mecp2 expression after decitabine treatment (day 2) and decitabine withdrawal (day 8). All graphs represent the Pearson's correlation
coefficient (r) for Mecp2e1 (black), and Mecp2e2 (pink): statistical significance: ***P <0.001; **P <0.01; *P <0.05; n = 3. (A) Correlation coefficients for
the relation between Mecp2 expression and average methylation over entire regions in Mecp2 promoter (region (R)1 to R3) and intron 1 (R4 to
R6) after decitabine exposure on day 2 (D2) (a), and after decitabine withdrawal on D8 (b). (B) After decitabine exposure: correlation coefficients
for Mecp2e1 (black), and Mecp2e2 (pink) with individual CpG methylation at the promoter regions (a) R1, (b) R2 and (c) R3, and intron 1 regions
(d) R4, (e) R5 and (f) R6. (C) After decitabine withdrawal: correlation coefficients for Mecp2e1 (black), and Mecp2e2 (pink) with individual CpG
methylation at promoter regions (a) R1, (b) R2 and (c) R3, and intron 1 regions (d) R4, (e) R5 and (f) R6. Statistical significance: *P <0.05; n = 3.
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the only CpG site within R5 showed negative, significant
correlation with Mecp2e1 (r > −0.8, P <0.05) (Figure 7B, e).
Interestingly, at D8 intron 1 R4 and R6 showed positive,
significant correlation with the Mecp2e2 isoform (r >0.8,
P <0.05) (Figure 7C, d-f). The observed correlations for all
REs are represented in Figure 7B-C and are summarized in
Figure 8.
Taken together, these results show a strong (r > 0.8,
P <0.05) and dynamic (positive or negative) relationship
between DNA methylation at the Mecp2 REs and ex-
pression of Mecp2 isoforms depending on the different
stages of NSC differentiation. Therefore, these results
implicate a possible dynamic role of DNA methylation at
the Mecp2 REs in regulating Mecp2 isoform-specific
expression.
Discussion
In the brain, precisely controlled MECP2/MeCP2 tran-
script and protein expression levels are critical, as even
slightly altered expression is associated with severe
neurological symptoms [2,16,57-60]. However, so far lit-
tle is known about how MeCP2 expression is regulated
in the developing brain. MeCP2 is a major epigenetic
regulator in brain, and its reduced expression in the aut-
istic brain is associated with MECP2 promoter hyperme-
thylation [2]. Surprisingly, the role of DNA methylation
in MeCP2 expression during brain development is un-
clear. Currently, most diseases that are associated with
aberrant MeCP2 function or expression deficits, includ-
ing autism and Rett syndrome, have no cure or effective
treatment. This underscores an urgent need for investi-
gating how MeCP2 expression is regulated in the brain.
Such knowledge for addressing this gap is essential for
designing possible future therapeutic strategies. DNA
methylation is a reversible epigenetic modification [22],
which can be targeted by existing Food and Drug
Administration (FDA)-approved drugs, including decita-
bine, which is suggested for use in autism [61,62].
Therefore, investigating the effect of such epigenetic
drugs on MeCP2 expression is important. Therapeutic
approaches such as gene therapy or restoring MeCP2
expression by genetic engineering have been suggested
as possible therapeutic strategies for MeCP2-associateddisorders [14,15,35]. However, even mild MeCP2 overex-
pression can lead to severe neurological complications,
highlighting the importance of understanding MeCP2
regulatory mechanisms. Since both MeCP2 isoforms
have been implicated in severe neurological disorders,
investigating MeCP2 regulation is equally important for
individual isoforms. This present study is the first report
on the potential role of DNA methylation at the Mecp2
REs and the impact on the expression of Mecp2
isoforms.
We observed globally altered DNA methylation upon
decitabine exposure and withdrawal. Since DNA methy-
lation is a major epigenetic mechanism that is involved
in modulating gene expression and chromatin architecture
[22], these observed changes in 5mC levels may possibly
lead to altered chromatin structure and genome-wide
changes in gene expression. Furthermore, the presented
findings highlight that exposure to drugs that disturb the
epigenetic marks during differentiation of brain cells may
lead to aberrant DNA methylation profiles. Our observa-
tions at D8 indicate that, even after the disturbance factor
is withdrawn from the system, an epigenetic memory for
this disturbance may be associated throughout cellular dif-
ferentiation of brain cells. Thus, our findings highlight the
biological importance of maintaining proper regulation of
epigenetic factors/modifications during brain development
with a clear focus on DNA methylation and MeCP2.
Our results show that decitabine alters Mecp2/MeCP2
expression at both the transcript and protein levels. Im-
portantly, even minor changes in Mecp2 transcript ex-
pression led to nearly 2- to 3-fold altered protein
expression, highlighting the biological significance of
proper regulation of Mecp2 expression at the transcript
levels. The observed correlation between the Mecp2/
MeCP2 (total) and Mecp2e1/MeCP2E1 transcript/pro-
tein expression at D2 reinforces the concept that poten-
tial changes in Mecp2 transcript levels may reflect
possible changes at the protein levels. However, the non-
correlated Mecp2/MeCP2 (total) and Mecp2e1/MeCP2E1
transcript/protein expression at D8 indicates that decita-
bine withdrawal causes not only transcriptional but also,
post-transcriptional regulation of MeCP2 expression, lead-
ing to reduced expression of MeCP2 (total)/MeCP2E1.
One such post-transcriptional regulatory mechanism
Figure 8 Summary of the correlations between the expression of Methyl CpG binding protein 2 gene (Mecp2) isoforms and DNA
methylation at the Mecp2 regulatory elements. (A) Dynamic changes in the expression of Mecp2 isoforms (Mecp2e1 and Mecp2e2) at different
time points of neural stem cell (NSC) differentiation at day 0 (D0), D2 and D8. Decitabine caused upregulation of Mecp2e1/MeCP2E1 but not
Mecp2e2 at D2. Decitabine effect on MeCP2E2 at the protein levels is unknown. Decitabine withdrawal by D8 downregulated Mecp2e1/MeCP2E1,
and Mecp2e2/MeCP2E2 (unknown) to different extents. (B) Schematic representation of the correlation between Mecp2 isoform-specific expression
and DNA methylation at the Mecp2 promoter regions (R1 to R3), and intron 1 regions (R4 to R6). The size of the signs, plus (+), and minus (−)
represents the relative degree of correlation with either Mecp2 isoform. The statistically significant correlations are represented in red (red-circled
plus, red-circled minus). After decitabine exposure Mecp2e1 expression negatively correlated with promoter R1 and R3, and intron 1 R5. Mecp2e2
isoform negatively correlates with promoter R3. In contrast, after decitabine withdrawal, Mecp2e1 expression negatively correlated with promoter
R1, R2 and R3, and positively correlated with intron 1 R6. Hence, correlation between Mecp2e1 and DNA methylation at REs changed depending
on the stage of NSC differentiation. Mecp2e2 isoform positively correlated with intron 1 R4 and R6.
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pression of which has been shown to be increased by 5-
aza-2′-deoxycytidine/decitabine [63], and has the ability
to repress MeCP2 expression [64].
Increased promoter methylation of autistic candidate
genes such as RORA, BCL2 and MECP2 are shown to be
associated with reduced expression of these genes in aut-
istic patients [2,19,62]. Treatment with decitabine wasshown to demethylate promoters and restore/induce the
expression of the silenced RORA and BCL2 in autistic
and patients with fragile X syndrome and hence, the use
of DNA demethylating agents in drug therapy for autism
and fragile X syndrome has been suggested [61,62]. A
similar strategy to restore/induce MeCP2 expression
might be extended to treat such diseases associated with
reduced MeCP2 expression, including autism and RTT.
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plication of epigenetic drug therapy to induce non-
mutated copy of MECP2 expression in Rett syndrome
cell lines has been suggested and attempted previously
[65]. Therefore, our findings on the ability of decitabine
to induce MeCP2 expression in differentiating NSC pro-
vide further insights on designing possible drug therap-
ies for autism. Even though the exposure of RTT cell
lines (fibroblasts) to lower doses of decitabine for a lon-
ger period did not activate MECP2 expression [65], our
results indicate that moderate dose of decitabine can in-
duce Mecp2/MeCP2 expression within a shorter period.
However, inhibition of MeCP2 by withdrawal of decita-
bine as well as other observed changes in DNA methyl
marks implies that such drug therapy should be admin-
istrated with great caution.
Our findings on the changes in DNA methylation at
the Mecp2 REs are in agreement with the previous re-
ports on MECP2 promoter methylation, which demon-
strate that an approximate difference of 2.0 to 2.5%
overall methylation over a region −233 to −531 up-
stream of the MECP2 promoter is correlated with re-
duced MECP2 expression in autistic male brains. The
authors report that within the 15 CpG sites found in this
MECP2 promoter region, two CpG sites are specifically
altered in the autistic males [2]. Furthermore, our results
are in agreement with a previous report on significantly
reduced MeCP2 expression in the postnatal mouse brain
(under stress), which is associated with 2 to 5% in-
creased methylation at the individual CpG sites within a
164-bp region of the Mecp2 promoter [20]. Supporting
these observations, studies have also shown minor differ-
ences, such as 2 to 5% DNA methylation causing signifi-
cant changes in the expression of other genes, such as
RASSF1, in the human brain [66], AMOTL2 in the hu-
man heart [67], and PGC1α in human muscles [68].
Therefore, although the detected DNA methylation
changes in this current study are not considerably high
(they varied between 2 to 15%), they were statistically
significant for average DNA methylation (within R1, R3
and R5) during NSC differentiation, and for several spe-
cific CpG dinucleotides subsequent to decitabine treat-
ment (within R2, R4, R5, and R6), and are likely to be
biologically important.
The Mecp2 promoter CpG island studied by Franklin
et al., [20] overlaps with the R1 and R2 of the Mecp2
promoter that we studied here. The significantly methyl-
ated CpGs reported in their study coincides with the R2
CpGs, where we observed changes at individual CpG
sites as well as average methylation upon decitabine
treatment. However, in our study we did not see any sig-
nificant change in the R1 CpG sites (both D2 and D8),
where Franklin et al., reported DNA methylation
changes. Importantly, the results we obtained for one ofthe promoter regions studied (R2) are in agreement with
this previous report, which showed a biological and
functional importance of the methylation changes in
regulating MeCP2 expression in response to stress
in vivo. Therefore, it is likely that the detected changes
we observed in the Mecp2 REs in our study also have
biological importance. The hypermethylation of this R2
region in mouse brain was associated with MeCP2
downregulation [20], and hence it is possible that the hy-
pomethylation/demethylation of the same R2 region
causes Mecp2/MeCP2 upregulation.
Our results on the ability of 2.5 μM decitabine to up-
regulate Mecp2e1 (but not Mecp2e2) suggest that the
two isoforms may have different sensitivities to drugs/
chemicals. This observation is in agreement with the
previous report on the higher sensitivity of Mecp2e1
than Mecp2e2 to Bisphenol A [69]. These observations
further suggest that the differential sensitivity to drugs
might be used to specifically induce only one Mecp2 iso-
form. This is also important because overexpression of
Mecp2e2, but not Mecp2e1 causes neuronal cell death
[10]. Hence, our study provides a functional relevance of
DNA demethylation at the Mecp2 REs by decitabine
causing upregulation of Mecp2e1, but not Mecp2e2.
The observed negative correlation between the expres-
sion of both Mecp2 isoforms and Mecp2 promoter ele-
ments are novel and are in accordance with previous
correlation studies on the human MECP2 expression
and promoter DNA methylation [2,19]. Furthermore,
our study is novel in demonstrating a dynamic (positive/
negative) correlation between the intronic DNA methy-
lation and expression of Mecp2 isoforms in differentiat-
ing brain cells. It is possible that the promoter regions
analyzed in our study (which also overlap with the core
Mecp2 promoter [13]) might be shared by both Mecp2
isoforms, whereas depending on the stage of neural dif-
ferentiation, intron 1 regions may add another layer of
regulation for Mecp2 isoform-specific expression. Sup-
porting our findings, the role of intronic DNA methyla-
tion in regulating gene expression of other genes has
been previously reported [70,71]. Several other reports
also show evidence that gene expression negatively cor-
relates with promoter methylation and positively corre-
lates with gene-body methylation [67,72].
Intronic DNA methylation is reported to be involved
in regulating alternative splicing [27,28]. Although, it is
known that Mecp2 isoforms are generated by alternative
splicing [4,5], the underlying molecular mechanisms are
still unclear. We observed that the expression ratio of
Mecp2e1/Mecp2e2 changed during NSC differentiation.
The observed correlation between the splice ratio and
intron 1 R4 DNA methylation in differentiating NSC at
D2 would provide insights on the potential importance
of this region in Mecp2 alternative splicing.
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nated as part of a silencer element, which has been pre-
viously proposed to regulate MECP2 alternative splicing
and tissue-specific expression [12]. Our findings are in
agreement with possible involvement of these regions in
Mecp2 isoform-specific expression. Although the link
between DNA methylation and Mecp2 expression is sup-
ported by our results in the NSC system, the contribu-
tion of other epigenetic modifications such as histone
acetylation and histone methylation should not be
excluded [73,74].
Conclusion
The summary of the findings presented in our study is
illustrated in Figure 8. First, expression of Mecp2 iso-
forms was significantly and reciprocally changed at dif-
ferent stages of NSC differentiation, in association with
minor but significant changes in DNA methylation at se-
lected Mecp2 REs, suggesting possible involvement of
these regions in Mecp2 regulation. Second, treatment of
differentiating NSC with decitabine for 48 h led to de-
methylation of specific Mecp2 REs (promoter R2 and all
intron 1 regions) and subsequent upregulation of
Mecp2e1/MeCP2E1 (but not Mecp2e2), implying the dif-
ferential sensitivity of the two Mecp2 isoforms to decita-
bine. Such differential sensitivity of Mecp2 isoforms to
decitabine might be useful in future drug therapies to
specifically activate one isoform but not the other. Fur-
thermore, the ability of decitabine to induce Mecp2e1/
MeCP2E1 at both transcript and protein levels provide
insights for future therapeutic strategies for MeCP2
deficiency-related neurodevelopmental disorders such as
autism and Rett syndrome. Finally, the significant and
dynamic (positive or negative) correlation between the
expression of Mecp2 isoforms and DNA methylation im-
plies the potential contribution of these REs in regulating
Mecp2 isoforms at different stages of neural differenti-
ation. Collectively, our study contributes to the under-
standing of expression and regulation of Mecp2 isoforms
during neural development and provides important in-
sights for future therapeutic applications of decitabine for
MeCP2-related neurological disorders.
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Additional file 1: Figure S1. Comparison of CpG sites in human Methyl
CpG binding protein 2 gene (MECP2) and mouse Methyl CpG binding
protein 2 gene (Mecp2) promoter and intron 1. CpG sites analyzed in the
mouse Mecp2 (black) are underlined. Conserved CpGs between mouse
and human sequences are also underlined in human MECP2 (red)
sequence.
Additional file 2: Figure S2. Detection of KI67 in day 2 (D2) control
cells. KI67 was detected in (98.8% ± 0.8) of the D2 cell population,
indicating that they were actively proliferating. Scale bars represent
20 μm.Additional file 3: Figure S3. Relationship between the ratio of mouse
Methyl CpG binding protein 2 gene Mecp2 splice variants and DNA
methylation at selected Mecp2 regulatory elements. Pearson’s correlation
analysis between DNA methylation at the Mecp2 regions R1, R4 and R5
and Mecp2e1/Mecp2e2 ratio at different stages of neural stem cell (NSC)
differentiation. Significant differences: *P <0.05. The regions are, promoter
regions R1: CpG island contains 13 CpG sites, intron 1 regions R4: 1 CpG
site, and R5: 1 CpG site; n = 3 ± standard error of the mean.
Additional file 4: Figure S4. Determination of the male/female
contribution at different stages of neural stem cell (NSC) differentiation.
(A) PCR amplification of Sry (402 bp) and Il3 (544 bp) in adult male cortex
(positive control) and the absence of the signal in negative control PCR
(no template). (B) The detection of Sry and Il3 in the positive and
negative controls and during NSC differentiation (day 0 (D0), D2, D8). The
graph represents ratio of Sry/Il3; n = 3 ± standard error of the mean (SEM).
(C) Expression of Xist transcripts relative to Gapdh at different stages of
NSC differentiation; n = 3 ± SEM. Significance was determined at *P <0.05.
(D) Ratio of Sry/Il3 in D2 control and D2 decitabine-treated cells. (E) Ratio
of Sry/Il3 in control and decitabine-treated cells at D8; n = 3 ± SEM. Ex-
pression of Xist transcripts relative to Gapdh at D2 after decitabine treat-
ment (F), and at D8 after decitabine withdrawal (G); n = 3 ± SEM.
Significance was determined at *P <0.05.
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